-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 5th China International Import Expo is in full progress, as the earliest "full" exhibition area, medical equipment and medicine health care hall is still hot this year, with an exhibition area of about 70,000 square meters, "squeezed" into more than 33 countries and regions more than 350 enterprises to participate in the exhibition
.
At this year's Expo, the world's 15 pharmaceutical giants, such as Johnson & Johnson, Pfizer, Roche Pharmaceutical, AbbVie, Novartis, Merck, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, AstraZeneca, Takeda Pharmaceutical, Eli Lilly, Bayer, Gilead, Amgen, etc.
, gathered
for the first time in five years.
As the world's second largest pharmaceutical and health market, China has become a "must-fight place"
for multinational pharmaceutical companies.
This year's Expo also gathered the "debut", "first launch" and "first launch" of many pharmaceutical companies to show their innovative technological strength
to the world.
"CIIE not only creates a platform to promote global innovation exchanges and development, but also fully demonstrates China's determination
to expand opening up and share development opportunities.
" Guohong, Shan Guohong, Senior Vice President of Takeda Pharmaceutical and President of Takeda China, said, "Takeda Pharmaceutical is full of confidence in the long-term development and growth potential of China's healthcare industry"
.
Since the first CIIE in 2018, Takeda Pharmaceutical's 9 innovative products have been approved in China, and these products have been displayed
at previous CIIEs.
In recent years, Takeda Pharmaceutical's innovative drugs and breakthrough therapies have been approved in China at a record
pace.
At this Expo, Sanofi vaccine brought Beyfortus (nirsevimab), the world's first and only respiratory syncytial virus (RSV) prevention method that can be widely used in newborns and infants, which is also the world premiere of this product; Takeda Pharmaceutical unveiled eight world-first, best-in-class innovative products and breakthrough therapies in core areas such as digestion, oncology, and rare diseases.
Bayer offers chronic heart failure treatment drugs with a new mechanism of action; Janssen, a pharmaceutical subsidiary of Johnson & Johnson, exhibited for the first time a revolutionary therapy
for the improvement of multiple myeloma.
For multinational pharmaceutical companies, it is not the first time that the world's cutting-edge innovation achievements have been unveiled at the
Expo.
Thanks to the "spillover" effect of the Expo, a number of world-leading innovative products participating in the exhibition have accelerated their approval, listing and access in China, changing from "exhibits to commodities", constantly refreshing the "new identity of China", and benefiting more Chinese patients and people
.
The targeted human anti-interleukin-5 (IL-5) monoclonal antibody Xinkelai, which has once again appeared on the stage of Jinbo this year, is a successful case
of GlaxoSmithKline using the Jinbo effect.
In 2021, after the "debut" of the Expo, Xinkelai was approved by the State Food and Drug Administration for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA) within two weeks, and issued its first prescription in July this year, rapidly realizing the identity leap
from "first exhibition" to "first place".
At present, China's biopharmaceutical industry is experiencing industry changes led by "innovation", taking advantage of the opportunities in China's pharmaceutical market and taking advantage of the Expo stage, multinational pharmaceutical companies have also frequently started various cooperation with local enterprises, accelerated the localization process, and created a new medical ecological "circle of friends"
.
Song Weiqun, senior vice president of Johnson & Johnson and chairman of China, said that the strong "spillover effect" of Jinbo in five years not only promoted "exhibits into commodities", but also drove Johnson & Johnson from "exhibitors to investors"
.
For example, Johnson & Johnson Med's new generation of antibacterial Vijo absorbable sutures, which had landed at the Expo as an imported product, was successfully localized in Johnson & Johnson Suzhou Industrial Park in January this year, filling the industry gap
in this production field in China.
Zhang Heping, head of Sanofi Vaccine Greater China, said that Sanofi has been in China for four decades and has been increasing its investment
in the Chinese market.
Sanofi introduced China's first and currently the only foreign-funded vaccine factory in Shenzhen and established China's first international vaccine innovation center
.
"China's local vaccine companies are gradually accelerating international cooperation, and a large number of domestic and foreign scientists, professional and technical personnel have entered the field of Chinese vaccines, I believe that the future of China's vaccine exhibition is getting better and better, and ranking among the world's advanced level
.
"
"In the future, China will become one of the important sources of
global pharmaceutical innovation.
" Shan Guohong said that China's pharmaceutical innovation is being integrated into the global innovation system, and Takeda Pharmaceutical will promote the results of global innovation to China
at a faster speed.
China plays a vital role in Takeda's R&D strategy and has become one of
four key R&D regions alongside the United States, Japan and Europe.
During the Expo, Bayer Consumer Health and the team of Professor Ma Guansheng of Peking University School of Public Health held the unveiling ceremony
of the expert work service station of the "Science and Technology Innovation China" Smart Health Professional Science and Technology Service Group.
He Yong, General Manager of Bayer Consumer Health China, said that it will accelerate the pace of innovation, consolidate the foundation of cooperation, improve service capabilities, and work with all parties to build a "healthy China"
.
(End)
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
